ALX Oncology Holdings Inc. cash flow to debt ratio of -1.61K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ALX Oncology Holdings Inc.'s free cash flow has increased -31.06% from $-122.36M last year to $-84.35M, signaling increasing performance

ALX Oncology Holdings Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

ALX Oncology Holdings Inc.'s debt has decreased relative to shareholder equity from 0.15 last year to 0.07 today, signaling strengthened financials

ALX Oncology Holdings Inc. has a net cash position, so leverage is healthy.

ALX Oncology Holdings Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

ALX Oncology Holdings Inc. has insufficient data to evaluate this check.

ALX Oncology Holdings Inc.'s short-term assets of $50.73M exceed its short-term liabilities of $24.55M

ALX Oncology Holdings Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ALX Oncology Holdings Inc.'s return on equity of -90.30%, is lower than 15.00%, indicating bad performance

ALX Oncology Holdings Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ALX Oncology Holdings Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

ALX Oncology Holdings Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ALX Oncology Holdings Inc. has negative free cash flow, indicating cash burn

ALX Oncology Holdings Inc.'s yearly earnings has increased -24.59% since last year from $-134.85M to $-101.69M, signaling increasing performance

ALX Oncology Holdings Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -56.53% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ALX Oncology Holdings Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

ALX Oncology Holdings Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

ALX Oncology Holdings Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ALX Oncology Holdings Inc. has insufficient data to evaluate this check.

ALX Oncology Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ALX Oncology Holdings Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ALX Oncology Holdings Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ALX Oncology Holdings Inc. has insufficient data to evaluate this check.

ALX Oncology Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ALX Oncology Holdings Inc. has a price-to-book ratio of 2.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ALX Oncology Holdings Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue